Learning from Nature, learning from our Ancestors; from tradition to evidence based medicines
- Thursday 14 April 2016 - Friday 15 April 2016
2300 RA Leiden
The symposium is a direct follow up of last year’s recognition of natural products as source of novel medicines through the Nobel prize for Medicine to two projects:
- The development of 'artimisinin' as a novel antimalarial medicine based on a traditional Chinese medicine.
- The discovery of a new class of antibiotics by bioprospecting of microorganisms. The full development of these antibiotics supported by a pharmaceutical company resulted in a medicine to treat river blindness, a disease of the poor.
Apparently the medical world wanted to make a statement of the importance of nature for drug development, and for searching treatments of the diseases of the poor.
The program for the first day is the present, what are challenges in different disciplines involved? The second day is about the latest developments in various monodisciplines needed in multidisciplinary projects for a more systemic approach to understanding nature and traditional medicine.
April 14: the present
9.15-9.45 Big data, repositories: H. Cousijn (Elsevier, Amsterdam, NL)
9.45-10.15 Nagoya protocol: B. Visser (Wageningen, NL)
10.15-10.45 Plant names : M. Simmonds (Kew, UK)
11.15-11.45 Field studies: T. van Andel (Naturalis, Leiden)
11.45-13.00 Poster pitches
13.45-14.15 Primary Toxicology: B. van de Water (Leiden, The Netherlands)
14.15-14.45 Primary Pharmacology: N. Moore (Bordeaux, France)
14.45-15.15 Role Medicinal chemistry : G. Appendino (Torino, Italy)
15.30-16.00 Quality control connected with activity: A. Viljoen (Pretoria, South Africa)
16.00-16.30 Pharmacology of chemistry which is first? R.F. Witkamp (Wageningen, NL)
16.30-17.30 How to review a paper: J. van Harten (Elsevier, Amsterdam, NL)
15 April: the future Omics, Synergy, systems biology, new models
9.00-9.30 Antimicrobial screening: A. Fallarero (Helsinki, Finland)
9.30-10.00 Synergy and pro-drugs: G. Ulrich-Merzenich (Bonn, Germany)
10.00-10.30 Systems pharmacology: M. Danhof (LACDR, Leiden, NL)
11.00-11.30 Clinical trials: J. van Gerven (CHDR, Leiden, NL)
11.30-12.00 Metabolomics: Y.H. Choi (IBL, Leiden, NL)
12.00-12.30 Technology developments, Metabolomics, Proteomics: R. van der Heijden (Bruker, NL)
14.00-14.30 Transcriptomics: J. Memelink (IBL, Leiden, NL)
14.30-15.00 DNA barcoding: J. Novak (Vienna, Austria)
15.30-16.00 Anticancer screening: T. Efferth (Mainz, Germany)
16.00-16.30 Caenorhabditis elegans as model system: M. Wildwater (Utrecht, NL)
16.30-17.00 Zebra fish as model: H. Spaink (IBL, Leiden)